SCHEMBL24011194

SCHEMBL24011194

COc1ccc(CNC(=O)NC2CCN(C(=O)c3cccc(C)c3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.60
▸ HRH3 Q9Y5N1 1/20 0.60
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ CTDSP1 Q9GZU7 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ EPHX2 P34913 2/20 0.53
▸ GPR183 P32249 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ CRHBP P24387 1/20 0.51
▸ CRHR2 Q13324 1/20 0.51
▸ LMNA P02545 1/20 0.50
▸ TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24011203 0.92 NPC1 (0.60) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011230 0.90 EPHX2 (0.61) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011333 0.90 NPC1 (0.58) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011089 0.89 NPC1 (0.57) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011198 0.89 NPC1 (0.64) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011193 0.88 MCHR1 (0.70) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011324 0.88 NPC1 (0.55) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011326 0.88 GAA (0.57) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011091 0.88 NPC1 (0.55) MCHR1HRH3NPC1RAB9ASMN1; SMN2
SCHEMBL24011481 0.88 NPC1 (0.68) MCHR1HRH3NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
WO-2021226276-A2 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT MCHR1 360/4885HRH3 1432/4885NPC1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback